Ascendis Pharma A/S vs Celsius Holdings, Inc. — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.67B), while Celsius Holdings, Inc. trades at $27.98 (market cap $7.11B). The key difference: Ascendis Pharma A/S is far larger — about 2.3× Celsius Holdings, Inc.'s market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Celsius Holdings, Inc. nearer its low. Which is the better fit depends on your goals.
| ASND | CELH | |
|---|---|---|
Market Cap | $16.67B | $7.11B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $64.86 |
52-Week Low | $189.74 | $23.77 |
Enterprise Value | $17.04B | $8.90B |
Trailing returns across standard periods
Latest headlines on both assets
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →Celsius Holdings Inc engages in the development, marketing, sale, and distribution of functional calorie-burning beverages. It offers flavors including cola, orange, wild berry and lemon iced tea and non-carbonated flavors such as Raspberry Acai Green Tea and Peach Mango Green Tea under the Celsius brand name. The company distributes its products through direct-store-delivery distributors, as well as directly to retailers across various retail segments, including supermarkets, convenience stores, drug stores, nutritional stores, mass merchants, health clubs, spas, gyms, military, and e-commerce websites.
Read more on CELH →